98%
921
2 minutes
20
Background: The appendicular skeletal muscle mass index (ASMI) is an important risk indicator for osteoporosis because of the anatomical proximity and metabolic connection between muscle and bone mass. The present study investigated the relationship between ASMI and the bone mineral density (BMD) categories of postmenopausal women.
Methods: In this cross-sectional study with a probabilistic sample, sociodemographic, lifestyle, menopause time, anthropometric, and physical activity variables were collected. ASMI and BMD were assessed by dual-energy X-ray absorptiometry (DXA). Participants were grouped according to BMD values into normal density, osteopenia, and osteoporosis. Multivariate logistic regression models were applied to verify the influence of ASMI on BMD. Data were analyzed using the SPSS statistical software, version 22. The significance level for all tests was set at 5%.
Results: Of the 114 women analyzed, most were between 60 and 69.9 years of age (62.3%), on menopause for ≤19.0 (51.8%), self-declared brown race/color (49.1%), had < 4 years of education (41.2%), never smoked (69.0%) or drank alcohol (62.8%). Of these, 52.6% were classified as sufficiently active and 52.2% had regular sun exposure. Women with osteoporosis were older (p = 0.035), on menopause for a longer time (p = 0.011), underweight (p = 0.004), had adequate waist circumference (p = 0.017), and low ASMI values (p = 0.002). There was an association between the 1st tertile of ASMI and osteoporosis. However, after adjustments for age, race/color, and body mass index, the strength of association between BMD and ASMI was not maintained.
Conclusions: ASMI was not associated with the BMD of the postmenopausal women evaluated. Total body and muscle mass, in addition to bone mass, should be monitored during menopause treatment. Longitudinal studies must be conducted to elucidate the mechanisms and gaps in this relationship.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501937 | PMC |
http://dx.doi.org/10.1186/s12891-021-04748-x | DOI Listing |
Front Biosci (Landmark Ed)
August 2025
Division of Biochemistry and Molecular Biology, Siberian State Medical University, Ministry of Health of the Russian Federation, 634050 Tomsk, Russia.
Background: Sarcopenia is a complex, multifactorial condition characterized by progressive loss of muscle mass, strength, and function. Despite growing awareness, the early diagnosis and pathophysiological characterization of this condition remain challenging due to the lack of integrative biomarkers.
Objective: This study aimed to conduct a comprehensive multilevel profiling of clinical parameters, immune cell phenotypes, extracellular vesicle (EV) signatures, and biochemical markers to elucidate biological gradients associated with different stages of sarcopenia.
J Obes Metab Syndr
September 2025
Department of Endocrinology and Metabolism, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Background: This study explores how relative skeletal muscle mass is associated with the development of metabolic dysfunction-associated steatotic liver disease (MASLD) and the remission of baseline MASLD in a community-based population cohort.
Methods: The study included 1,544 participants with an average age of 58 years. All participants underwent baseline and follow-up assessments in 2015 or 2016.
J Frailty Aging
September 2025
Department of Geriatric Medicine, Klinikum Fürth, Fürth, Germany; Institute for Biomedicine of Ageing, Friedrich-Alexander-University, Erlangen-Nürnberg, Germany.
Purpose: Sarcopenia and sarcopenic obesity are defined by the loss of muscle strength and mass. Both diseases pose a growing global challenge. Their prevalences vary between studied populations.
View Article and Find Full Text PDFZhonghua Nan Ke Xue
July 2025
Department of Surgery, Yinchuan Hospital of Traditional Chinese Medicine, Ningxia Medical University, Yinchuan, Ningxia 750001, China.
Objective: To evaluate the clinical efficacy of "Shibao Decoction" in the management of late-onset hypogonadism (LOH) caused by deficiency of kidney essence.
Methods: Sixty male patients with late-onset hypogonadism of kidney essence deficiency type were randomly assigned to the treatment group and the control group, each with 30 cases. The patients in treatment group were treated with oral Shibao Decoction, while the control group was treated with oral Testosterone Undecanoate Capsules.
Front Med (Lausanne)
August 2025
Department of Non-communicable Diseases Control and Prevention, Shaoxing Center for Disease Control and Prevention, Shaoxing, China.
Background And Objectives: The impact of probable respiratory sarcopenia (RS) on the prevalence and incidence of chronic lung diseases (CLDs) in middle-aged and older adults remains poorly understood. This study utilized data from the China Health and Retirement Longitudinal Study (CHARLS) to explore this association.
Methods: A total of 6,614 participants aged 45 and above were included in a cross-sectional analysis in 2011, and 5,630 participants were followed for 7 years for longitudinal analysis.